Single-agent Bevacizumab in Recurrent Glioblastoma after Second-line Chemotherapy with Fotemustine the Experience of the Italian Association of Neuro-Oncology

Francesco Pasqualetti, Andrea Pace, Alessandra Gonnelli, Veronica Villani, Martina Cantarella, Durim Delishaj, Caterina Vivaldi, Alessandro Molinari, Sabrina Montrone, Alessia Pellerino, Federica Franchino, Davide Baldaccini, Giuseppe Lombardi, Ivan Lolli, Francesca Catania, Elena Bazzoli, Riccardo Morganti, Alessandra Fabi, Vittorina Zagonel, Guido BocciMaria Grazia Fabrini, Roberta Rudà, Riccardo Soffietti, Fabiola Paiar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Bevacizumab is an anti-vascular endothelial growth factor antibody used in the treatment of recurrent glioblastoma (GBM). Despite the large number of studies carried out in patients with recurrent GBM, little is known about the administration of this angiogenesis inhibitor after the failure of the second-line chemotherapy. Materials and Methods: In this retrospective multicenter study, on behalf of the Italian Association of Neuro-Oncology, we reported the results obtained in 51 patients with recurrent GBM treated with single-agent bevacizumab after the failure of second-line chemotherapy with fotemustine. Results: In March 2016, at the time of data analysis, 3 patients (14.4%) were still alive with stable disease, whereas 48 died due to disease progression.Kaplan-Meier estimated median survival from the diagnosis of GBM was 28 months (95% confidence interval [CI], 22.1-33.9mo). Median survival measured from the beginning of fotemustine and bevacizumab therapy were 11.3 (95% CI, 8.4-13.6mo) and 6 months (95% CI, 3.8-8.1 mo), respectively. The 6- and 12-month progression free survival rates from the beginning of bevacizumab treatment were 18% and 13%, respectively. Conclusions: On the basis of our data, in patients with recurrent GBM, the failure of a second-line chemotherapy with cytotoxic agents might not exclude the administration of bevacizumab as third-line chemotherapy.

Original languageEnglish
Pages (from-to)1272-1275
Number of pages4
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume41
Issue number12
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

fotemustine
Glioblastoma
Drug Therapy
Confidence Intervals
Angiogenesis Inhibitors
Survival
Cytotoxins
Vascular Endothelial Growth Factor A
Multicenter Studies
Disease-Free Survival
Disease Progression
Therapeutics
Survival Rate
Retrospective Studies
Bevacizumab
Antibodies

Keywords

  • antiangiogenic therapy
  • bevacizumab
  • fotemustine
  • glioblastoma
  • salvage chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Single-agent Bevacizumab in Recurrent Glioblastoma after Second-line Chemotherapy with Fotemustine the Experience of the Italian Association of Neuro-Oncology. / Pasqualetti, Francesco; Pace, Andrea; Gonnelli, Alessandra; Villani, Veronica; Cantarella, Martina; Delishaj, Durim; Vivaldi, Caterina; Molinari, Alessandro; Montrone, Sabrina; Pellerino, Alessia; Franchino, Federica; Baldaccini, Davide; Lombardi, Giuseppe; Lolli, Ivan; Catania, Francesca; Bazzoli, Elena; Morganti, Riccardo; Fabi, Alessandra; Zagonel, Vittorina; Bocci, Guido; Fabrini, Maria Grazia; Rudà, Roberta; Soffietti, Riccardo; Paiar, Fabiola.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 41, No. 12, 01.12.2018, p. 1272-1275.

Research output: Contribution to journalArticle

Pasqualetti, F, Pace, A, Gonnelli, A, Villani, V, Cantarella, M, Delishaj, D, Vivaldi, C, Molinari, A, Montrone, S, Pellerino, A, Franchino, F, Baldaccini, D, Lombardi, G, Lolli, I, Catania, F, Bazzoli, E, Morganti, R, Fabi, A, Zagonel, V, Bocci, G, Fabrini, MG, Rudà, R, Soffietti, R & Paiar, F 2018, 'Single-agent Bevacizumab in Recurrent Glioblastoma after Second-line Chemotherapy with Fotemustine the Experience of the Italian Association of Neuro-Oncology', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 41, no. 12, pp. 1272-1275. https://doi.org/10.1097/COC.0000000000000464
Pasqualetti, Francesco ; Pace, Andrea ; Gonnelli, Alessandra ; Villani, Veronica ; Cantarella, Martina ; Delishaj, Durim ; Vivaldi, Caterina ; Molinari, Alessandro ; Montrone, Sabrina ; Pellerino, Alessia ; Franchino, Federica ; Baldaccini, Davide ; Lombardi, Giuseppe ; Lolli, Ivan ; Catania, Francesca ; Bazzoli, Elena ; Morganti, Riccardo ; Fabi, Alessandra ; Zagonel, Vittorina ; Bocci, Guido ; Fabrini, Maria Grazia ; Rudà, Roberta ; Soffietti, Riccardo ; Paiar, Fabiola. / Single-agent Bevacizumab in Recurrent Glioblastoma after Second-line Chemotherapy with Fotemustine the Experience of the Italian Association of Neuro-Oncology. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2018 ; Vol. 41, No. 12. pp. 1272-1275.
@article{4f358c526b054ccd893fe7846adee88b,
title = "Single-agent Bevacizumab in Recurrent Glioblastoma after Second-line Chemotherapy with Fotemustine the Experience of the Italian Association of Neuro-Oncology",
abstract = "Objectives: Bevacizumab is an anti-vascular endothelial growth factor antibody used in the treatment of recurrent glioblastoma (GBM). Despite the large number of studies carried out in patients with recurrent GBM, little is known about the administration of this angiogenesis inhibitor after the failure of the second-line chemotherapy. Materials and Methods: In this retrospective multicenter study, on behalf of the Italian Association of Neuro-Oncology, we reported the results obtained in 51 patients with recurrent GBM treated with single-agent bevacizumab after the failure of second-line chemotherapy with fotemustine. Results: In March 2016, at the time of data analysis, 3 patients (14.4{\%}) were still alive with stable disease, whereas 48 died due to disease progression.Kaplan-Meier estimated median survival from the diagnosis of GBM was 28 months (95{\%} confidence interval [CI], 22.1-33.9mo). Median survival measured from the beginning of fotemustine and bevacizumab therapy were 11.3 (95{\%} CI, 8.4-13.6mo) and 6 months (95{\%} CI, 3.8-8.1 mo), respectively. The 6- and 12-month progression free survival rates from the beginning of bevacizumab treatment were 18{\%} and 13{\%}, respectively. Conclusions: On the basis of our data, in patients with recurrent GBM, the failure of a second-line chemotherapy with cytotoxic agents might not exclude the administration of bevacizumab as third-line chemotherapy.",
keywords = "antiangiogenic therapy, bevacizumab, fotemustine, glioblastoma, salvage chemotherapy",
author = "Francesco Pasqualetti and Andrea Pace and Alessandra Gonnelli and Veronica Villani and Martina Cantarella and Durim Delishaj and Caterina Vivaldi and Alessandro Molinari and Sabrina Montrone and Alessia Pellerino and Federica Franchino and Davide Baldaccini and Giuseppe Lombardi and Ivan Lolli and Francesca Catania and Elena Bazzoli and Riccardo Morganti and Alessandra Fabi and Vittorina Zagonel and Guido Bocci and Fabrini, {Maria Grazia} and Roberta Rud{\`a} and Riccardo Soffietti and Fabiola Paiar",
year = "2018",
month = "12",
day = "1",
doi = "10.1097/COC.0000000000000464",
language = "English",
volume = "41",
pages = "1272--1275",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Single-agent Bevacizumab in Recurrent Glioblastoma after Second-line Chemotherapy with Fotemustine the Experience of the Italian Association of Neuro-Oncology

AU - Pasqualetti, Francesco

AU - Pace, Andrea

AU - Gonnelli, Alessandra

AU - Villani, Veronica

AU - Cantarella, Martina

AU - Delishaj, Durim

AU - Vivaldi, Caterina

AU - Molinari, Alessandro

AU - Montrone, Sabrina

AU - Pellerino, Alessia

AU - Franchino, Federica

AU - Baldaccini, Davide

AU - Lombardi, Giuseppe

AU - Lolli, Ivan

AU - Catania, Francesca

AU - Bazzoli, Elena

AU - Morganti, Riccardo

AU - Fabi, Alessandra

AU - Zagonel, Vittorina

AU - Bocci, Guido

AU - Fabrini, Maria Grazia

AU - Rudà, Roberta

AU - Soffietti, Riccardo

AU - Paiar, Fabiola

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Objectives: Bevacizumab is an anti-vascular endothelial growth factor antibody used in the treatment of recurrent glioblastoma (GBM). Despite the large number of studies carried out in patients with recurrent GBM, little is known about the administration of this angiogenesis inhibitor after the failure of the second-line chemotherapy. Materials and Methods: In this retrospective multicenter study, on behalf of the Italian Association of Neuro-Oncology, we reported the results obtained in 51 patients with recurrent GBM treated with single-agent bevacizumab after the failure of second-line chemotherapy with fotemustine. Results: In March 2016, at the time of data analysis, 3 patients (14.4%) were still alive with stable disease, whereas 48 died due to disease progression.Kaplan-Meier estimated median survival from the diagnosis of GBM was 28 months (95% confidence interval [CI], 22.1-33.9mo). Median survival measured from the beginning of fotemustine and bevacizumab therapy were 11.3 (95% CI, 8.4-13.6mo) and 6 months (95% CI, 3.8-8.1 mo), respectively. The 6- and 12-month progression free survival rates from the beginning of bevacizumab treatment were 18% and 13%, respectively. Conclusions: On the basis of our data, in patients with recurrent GBM, the failure of a second-line chemotherapy with cytotoxic agents might not exclude the administration of bevacizumab as third-line chemotherapy.

AB - Objectives: Bevacizumab is an anti-vascular endothelial growth factor antibody used in the treatment of recurrent glioblastoma (GBM). Despite the large number of studies carried out in patients with recurrent GBM, little is known about the administration of this angiogenesis inhibitor after the failure of the second-line chemotherapy. Materials and Methods: In this retrospective multicenter study, on behalf of the Italian Association of Neuro-Oncology, we reported the results obtained in 51 patients with recurrent GBM treated with single-agent bevacizumab after the failure of second-line chemotherapy with fotemustine. Results: In March 2016, at the time of data analysis, 3 patients (14.4%) were still alive with stable disease, whereas 48 died due to disease progression.Kaplan-Meier estimated median survival from the diagnosis of GBM was 28 months (95% confidence interval [CI], 22.1-33.9mo). Median survival measured from the beginning of fotemustine and bevacizumab therapy were 11.3 (95% CI, 8.4-13.6mo) and 6 months (95% CI, 3.8-8.1 mo), respectively. The 6- and 12-month progression free survival rates from the beginning of bevacizumab treatment were 18% and 13%, respectively. Conclusions: On the basis of our data, in patients with recurrent GBM, the failure of a second-line chemotherapy with cytotoxic agents might not exclude the administration of bevacizumab as third-line chemotherapy.

KW - antiangiogenic therapy

KW - bevacizumab

KW - fotemustine

KW - glioblastoma

KW - salvage chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85054550317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054550317&partnerID=8YFLogxK

U2 - 10.1097/COC.0000000000000464

DO - 10.1097/COC.0000000000000464

M3 - Article

AN - SCOPUS:85054550317

VL - 41

SP - 1272

EP - 1275

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 12

ER -